Business
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrlzyJKRPwSh_YtGafCgLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"text","content":"For an accessible version of this Press Release, please visit www.tevapharm.com","length":79,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"AJOVY® – global revenues of $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024. Reaffirming $600M 2025 revenue outlook.","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"UZEDY® continues strong momentum – global revenues of $39 million in Q1 2025.","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"The generics business grew across all regions – increased by 5% in the U.S., 1% in Europe and 2% in International Markets, all in local currency terms, as compared to Q1 2024.","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":987,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Duvakitug (Anti-TL1A) Phase 3 ready; program initiation expected in H2 2025; preparing for olanzapine LAI FDA NDA submission in H2 2025.","length":136,"tagName":"p"}]},{"val...